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Preclinical models of schizophrenia
As in several previous instances, the International Journal
of Neuropsychopharmacology, the ofﬁcial journal of the
CINP, publishes high-level reviews based on presenta-
tions made at CINP Congresses. The following Section
of this Issue of the International Journal of Neuropsycho-
pharmacology contains four review articles written by
speakers of two different symposia at the 28th Congress
of the CINP, which took place in Stockholm, Sweden,
in June, 2012. The four articles review different pre-
clinical models of schizophrenia, covering cellular, neuro-
chemical, electrophysiological and behavioral studies
and summarize recent advances in the ﬁeld made at the
presentations by four speakers, (Mark A. Geyer, Javier
González-Maeso, Herbert Y. Meltzer and Francesc
Artigas).
The article by Halberstadt and Geyer reviews the use
of serotonergic hallucinogens as preclinical models of
schizophrenia and the use of these agents in four different
behavioral models, as well as the neurochemical mechan-
isms involved and their translational value. Likewise, the
article by Moreno and Gonzalez-Maeso reviews the role
of 5-HT2A and mGluR2/3 receptors in the neurobiology
and treatment of schizophrenia, also paying attention to
the involvement of such receptors in some preclinical
and behavioral models. The article by Meltzer et al
reviews the effects of subchronic treatment with non-
competitive NMDA receptor antagonists on the novel
object recognition test, a rodent model of declarative
memory, as well as the reversal of these effects by atypical
antipsychotics and other receptor ligands, in order to
identify new targets for treatment of some cognitive deﬁc-
its in schizophrenia. Finally, the article by Celada et al
reviews the alterations produced on thalamo-cortical cir-
cuits by serotonergic hallucinogens and non-competitive
NMDA receptor antagonists and the reversal of these
effects by classical and atypical antipsychotic drugs.
Overall, the four articles provide the reader with a
timely overview of relevant preclinical models of schizo-
phrenia which will help to identify new targets for the
development of new drugs for the treatment of schizo-
phrenia symptoms which are poorly treated by current
drugs. We thank the speakers for ﬁnding the time in
their busy schedules to write these reviews and hope
that this initiative will continue at future CINP
Congresses, starting with the 29th Congress next year in
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